-Armis Biopharma Announces Receipt of $20.3 Million Contract with the Defense Threat Reduction Agency to Develop Veriox® DECON for Battlefield Wounds
FORT COLLINS, Colo., Oct. 4, 2023 /PRNewswire/ -- Armis Biopharma, Inc. today announced that the company has received a $20.3 million contract from the Defense Threat Reduction Agency (DTRA) to develop its patented Veriox® DECON chemical warfare agent (CWA) decontamination product for use on battlefield wounds. This will be an important product for warfighters who may be exposed to chemical warfare agents when injured, as the technology could have the potential to help save lives and expand the opportunity to provide an adequate level of care to the seriously injured. The May 2023 issue of DTRA JSTO's publication, "JSTO in the News," included the article "Beyond a Bandage," which explains the importance of Veriox® DECON technology for military personnel.
Armis Veriox® technology (Veriox® DECON) was founded to neutralize chemical warfare agents in two separate studies conducted by the US Army Medical Research Institute of Chemical Defense (USAMRICD).
"We are excited by the opportunity to offer a new technology to decontaminate chemical warfare agents for application in the civil and military markets. Our unique patented solution, Veriox® DECON, offers several advantages over existing decontamination products for both individual and for mass casualty environments because it can be dispensed rapidly with standard liquid dispensing systems that will allow first responders to quickly decontaminate multiple people," said Ted Ziemann, President and CEO of Armis Biopharma. "Veriox® DECON is also environmentally safe because it breaks down quickly into harmless products and demonstrates a better safety profile than competing products."
In November 2020, Armis Biopharma received a grant from the National Institutes of Health to develop Veriox® DECON to provide first responders working in mass casualty decontamination with a rapid, effective and cost-effective application to neutralize chemical warfare agents in the skin. That application is currently being worked on.
In addition to nerve agent decontamination, Veriox® DECON is also a highly effective antimicrobial agent, which has demonstrated excellent efficacy against biological warfare agents (BWA) and drug-resistant pathogens and has also been successfully tested against fentanyl.
About Armis Biopharma
Armis Biopharma, Inc is a privately held biopharmaceutical company based in Fort Collins, CO, dedicated to developing and commercializing products that are effective in reducing the risk of infectious diseases, decontaminating chemical warfare agents, and providing differentiated medical devices. Product development focuses on surface disinfection, human and animal wound care, oral care, food safety, and decontamination of chemical and biological warfare agents.
Armis introduced its first antimicrobial surface disinfectant called ArmiClenz® in June 2020, its FDA-approved VeriFixx® small bone implant in November 2020, ArmiCare® hand sanitizer in 2021, ArmiVET® Animal Wound Wash in 2021, the ArmiGard™ cleaner for oral devices in 2022, and most recently, its FDA-approved VeriCyn® wound wash in May 2023. More products will follow in development beginning in 2024.
For more information about Armis, visit www.armisbiopharma.com.
For general questions contact info@armisbiopharma.com.
Media Contact:Karen Dombekkarend@mcspr.com
Logo - https://mma.prnewswire.com/media/2237912...
View original content: https://www.prnewswire.com/news-releases/armis-biopharma-anuncia-un-contrato-con-la-agencia-de-reduccion-de-amenazas-de-defensa-301946281.html
